Navigation Links
PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer

BOSTON, July 16 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, announced today that it has promoted Mark A. Goldberg, M.D., to Chief Operating Officer (COO). Dr. Goldberg previously served as President of Clinical Research Services and Perceptive Informatics at PAREXEL. He will continue to oversee these areas of the Company and report to Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL.

"Dr. Goldberg has been an asset to PAREXEL's executive management team for more than 11 years. His appointment as COO is in recognition of his strong leadership skills and increasing responsibilities, especially as we have expanded our clinical development capabilities and global footprint, including the recent extension of our capabilities in the Asia-Pacific region," said Mr. von Rickenbach. "Dr. Goldberg has led the strong performance in Clinical Research Services, our largest business segment, and has helped to build Perceptive Informatics into a leading provider of advanced technologies that facilitate the clinical development process. We look forward to his continued contributions in meeting our operational and financial goals, and solidifying our position as a global leader in full service clinical development."

Dr. Goldberg stated, "In this role, I look forward to working with our global management team to capitalize on the strong market opportunity for global biopharmaceutical services. My focus will include further strengthening our client relationships, as well as leveraging PAREXEL's leadership role in the convergence of services and technology in support of clinical research."

Dr. Goldberg's combined medical, technical, and clinical research expertise has positioned him well to lead Clinical Research Services and Perceptive Informatics at PAREXEL. He joined PAREXEL in 1997, establishing the Company's Medical Imaging Group to leverage imaging data as a surrogate end point, or biomarker, in evaluating the safety and efficacy of new products. In 2000, Dr. Goldberg was involved in establishing Perceptive Informatics to deliver advanced technology solutions that improve development and commercialization processes for the biopharmaceutical industry. Today, Perceptive Informatics has a portfolio of products and services including medical imaging, Interactive Voice and Web Response Systems, and the industry-leading IMPACT(R) Clinical Trial Management System (CTMS), which has approximately 26,000 users-the largest global CTMS user-base. In 2005, Dr. Goldberg took responsibility for the Clinical Research Services business and has achieved strong performance in new business wins, revenue growth, and profitability improvement. During this time, he continued to expand the offerings of the business, which provides capabilities across a broad range of therapeutic areas and all phases of clinical research.

Prior to joining PAREXEL, Dr. Goldberg served as President and Director of WorldCare, Inc., a tele-health spin-off from Massachusetts General Hospital (MGH), which he helped found. Dr. Goldberg holds a degree in Computer Science and Engineering from the Massachusetts Institute of Technology (M.I.T.), and an M.D. degree from the University of Massachusetts Medical School. He completed residency training in Diagnostic Radiology at MGH where he also served as Chief Resident. Dr. Goldberg was a staff radiologist at MGH and maintains an appointment as Consultant in Radiology.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.


Jennifer Baird, Senior Director of Public Relations

PAREXEL International

Tel: +781-434-4409


Rebecca Passo

SHIFT Communications

Tel: +617-779-1817


SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
3. PAREXEL Expands Global Clinical Logistics Capabilities
4. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
5. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
6. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
7. PAREXEL Reaches Agreement To Acquire ClinPhone
8. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
9. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
10. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
11. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
(Date:10/8/2015)... and WAYNE, Pa. , ... and technology consulting firm, has announced the call for ... Pennsylvania , majoring in a life sciences ... a two-year period. In addition, the selected Clarkston Scholar ... mentoring with Clarkston Consulting and participation in Pennsylvania Bio ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 The 2015 Nobel ... The University of Texas at Dallas. Aziz Sancar , ... Dallas in 1977, is one of three ... cells continuously monitor and repair damaged DNA on a molecular level.  ... molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... , Oct. 8, 2015  The ALS Association, ... ALS Assistive Technology Challenge to revolutionize communication technology solutions ... --> ALS (amyotrophic lateral sclerosis) is ... in the brain and the spinal cord. Eventually, people ... muscle movement, which often leads to total paralysis and ...
Breaking Biology Technology:
... AARUHS, Denmark, July 6 ... the EmbryoScope(TM) Embryo,Monitoring System and EmbryoSlide(TM) tray have ... use in IVF. Unisense Fertilitech A/S also received,the ... installation and servicing of IVF incubators and related,accessories. ...
... Mass., July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... amend the $29.5 million of outstanding 8% Senior Convertible Notes ... on July 1, 2009 is effective as of 8:00 a.m. ... Agreements with holders of 87% of the Notes, which is ...
... , REYKJAVIK, Iceland, July 6 Scientists at deCODE genetics ... and the United States today present in the journal ... for basal cell carcinoma (BCC) that affect people with fair ... single-letter variants in the sequence of the human genome (SNPs) ...
Cached Biology Technology:
(Date:10/7/2015)... , October 7, 2015 NXTD ... focused on the growing mobile commerce market and creator ... E. Washington , former long- term executive at American ... --> NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ...
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
Breaking Biology News(10 mins):
... researchers have demonstrated a new and more effective method ... a research advancement that could have major implications ... of death in the Western world. The treatment ... Aaron Baker could allow doctors to bypass surgery and ...
... In a worst-case scenario simulation of a foot-and-mouth disease ... surveillance system and raising a more resilient breed of ... industry should an outbreak of foot-and-mouth disease (FMD) or ... very quickly, such as foot-and-mouth, the best way to ...
... This press release is available in ... biochemical interest given the importance and diversity of the functions ... and serve as fuel for a number of biological systems; ... and, moreover, play a key role in cell processes. Recently ...
Cached Biology News:
... 27kDa periplasmic enzyme from E. coli that ... nucleotide monophosphate (NMP) intermediates. Slower hydrolysis further ... 3-NMPs (1). RNase ONE Ribonuclease is one ... cleave a phosophodiester bond between any two ...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is ... be effective in inhibiting retroviral activity. ... BSA. Specificity: The specificity of ... ratio of the moles of ddC to moles ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
Biology Products: